Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating. The firm Read More
February 15, 2026
Tags :cutaneous sarcoidosis